Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases. December 2, 2025 Assessing risk ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

Alicia Morgans is joined by Alan Dal Pra and George Zhao to discuss updates to the PORTOS Trial. PORTOS is a gene signature developed to predict radiation therapy benefit in prostate cancer, built on ...

Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...

Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...

Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine Diet. December 1, ...

Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...

Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation.

Diane Newman shares her background in patient care, specializing in behavioral therapy. She communicates the challenge of misconceptions about her work, emphasizing the research-backed effectiveness ...

Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer (mCRPC) treatment. They review the current management algorithm, ...

At the 2025 UCSF-UCLA PSMA Conference, Emmanuel Antonarakis compares PSMA radioligand therapy trials in mCRPC for the post-ARPI, pre-chemotherapy setting. He examines PSMAfore (177Lu-PSMA-617), SPLASH ...

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...